What is Beechtree Diagnostics?
Beechtree Diagnostics is a provider of customizable laboratory testing solutions tailored for medical professionals. The company's service portfolio encompasses urine toxicology testing, blood testing, molecular testing, and pharmacogenomics (PGX) testing. These offerings are designed to support a diverse range of medical fields, including obstetrics, addiction treatment, and psychiatric care, as well as primary care, pain management, and employee health programs. Beechtree Diagnostics focuses on delivering high-quality laboratory services to enhance patient care and clinical decision-making.
How much funding has Beechtree Diagnostics raised?
Beechtree Diagnostics has raised a total of $859K across 2 funding rounds:
Debt
$350K
Debt
$509K
Debt (2020): $350K with participation from PPP
Debt (2021): $509K led by PPP
What's next for Beechtree Diagnostics?
The recent major strategic investment positions Beechtree Diagnostics for significant expansion and further development of its specialized lab testing services. This capital infusion is expected to fuel advancements in technology, broaden service offerings, and potentially increase market reach within the healthcare provider segment. The company's focus on critical areas like toxicology and pharmacogenomics suggests a strategic emphasis on precision medicine and data-driven patient management, aligning with current trends in healthcare innovation.
See full Beechtree Diagnostics company page
